2024-10-21
Participating in CPHI Worldwid
Novo's weight-loss drug Saxenda found to be safe, effective at reducing Bll of kids
Release Time: 2024-09-18
News Source: PharmaCompass
Author: SENOVA—Lucas
Novo Nordisk's older weightloss drug Saxenda (liraglutide) has shown promising results in safely treating obesity in children aged six to 12 years. This marks a significant development in the field of pediatric obesity treatment, as currently no medications are approved for children under 12 years. The 56-week trial involved 92 children and demonstrated that those receiving daily injections of Saxenda experienced a 7.4 percent reduction in BMl compared to a placebo group. These results are particularly noteworthy given the rising rates of childhood obesity. However, experts have cautioned about the long-term effects of such treatments on children's development.
